Epidemiology of nonmelanoma and melanoma skin cancer in Zagreb, Croatia.

Acta Dermatovenerol Croat

Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine, Salata 4 HR-10000 Zagreb, Croatia.

Published: April 2009

The purpose of this retrospective and hospital-based study was to evaluate the epidemiology of nonmelanoma and melanoma skin cancer at University Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine during the 2003-2006 period. The study yielded population based results on 2911 cases of skin tumors in 2402 patients out of 16938 biopsies performed at Laboratory of Dermatologic Histopathology, University Department of Dermatology and Venereology, Zagreb University Hospital Center nd School of Medicine during the study period. All newly diagnosed invasive and in situ skin cancers were recorded by use of the histopathology record forms. Basal cell carcinoma was most commonly identified in the histopathology material (n=2002), followed by squamous cell carcinoma (n=533), melanoma (n=46) and cutaneous lymphoma (n=35). Other, less common tumors were noted. The number of tumors, and differences in age, sex and localization were analyzed. During the study period, there was no increase in the total number of cases recorded: 4305, 4202, 4116 and 4315, respectively. Study results showed skin tumors to be mostly diagnosed in elderly population (median age, 71 years). There were no significant sex differences, with the exception of the adult age group in 2006. As expected, skin tumors were mostly found in sun-exposed areas with some specific localization of individual tumor types. Study results were consistent with recent literature data.

Download full-text PDF

Source

Publication Analysis

Top Keywords

skin tumors
12
epidemiology nonmelanoma
8
nonmelanoma melanoma
8
melanoma skin
8
skin cancer
8
university department
8
department dermatology
8
dermatology venereology
8
venereology zagreb
8
zagreb university
8

Similar Publications

Primary malignant melanoma of the vagina: A case report of a rare disease that is difficult to diagnose.

Medicine (Baltimore)

January 2025

Department of Obstetrics and Gynecology, Dong-A University, College of Medicine, Busan, Republic of Korea.

Rationale: Malignant melanoma is a rare cancer that accounts for approximately 1% of all cancers. Primary malignant melanoma of the female genital tract accounts for approximately 3% to 7% of all malignant melanomas, and 0.3% to 0.

View Article and Find Full Text PDF

Cellular protein expression is coordinated posttranscriptionally by an intricate regulatory network. The current presumption is that microRNAs (miRNAs) work by repression of functionally related targets within a system. In recent work, up-regulation of protein expression via direct interactions of messenger RNA with miRNA has been found in dividing cells, providing an additional mechanism of regulation.

View Article and Find Full Text PDF

BACKGROUND Vulvar melanoma during pregnancy is exceptionally rare. Hormonal and immunological changes in pregnancy have raised concerns about the potential for accelerated melanoma progression and poorer maternal outcomes. This case report describes an unusual presentation of vulvar melanoma in a pregnant patient, which rapidly progressed despite previous treatments, but resulted in a favorable fetal outcome.

View Article and Find Full Text PDF

Dermatofibrosarcoma protuberans: A clinical and pathological observational report of Asian samples from one center.

J Cancer Res Ther

December 2024

Department of Plastic and Reconstructive Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Background: Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade fibrohistiocytic tumor with malignant potential. It is considered to have a high local recurrence rate due to the characteristic invasion of the finger-like lesion into the soft tissues.

Method: This retrospective study presents details of 20 DFSP patients with a history of surgery and a long follow-up period.

View Article and Find Full Text PDF

Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer.

J Cancer Res Ther

December 2024

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People's Republic of China.

Article Synopsis
  • The study examines the effects of a combination therapy (apatinib and trastuzumab-based chemotherapy) on patients with primary trastuzumab resistance (PTR) in HER2-positive breast cancer.
  • A total of 20 PTR patients were treated, showing a clinical benefit rate of 55%, though no complete responses were observed, and median progression-free survival was 5.7 months.
  • While the treatment had manageable side effects, further research is recommended to better identify which PTR patients could potentially benefit from this therapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!